Performance assessment of a fully automated electro-chemiluminescence immunoassay system for serum S100B protein

E Anastasi, G Gennarini, C Del Monte, B Colaprisca, S Tartaglione, C Di Segni, A Angeloni

Article ID: 5205
Vol 32, Issue 4, 2018
DOI: https://doi.org/10.54517/jbrha5205
Received: 8 September 2018; Accepted: 8 September 2018; Available online: 8 September 2018; Issue release: 8 September 2018

Abstract

The altered expression levels of S100 proteins can lead to four different categories of diseases: diseases of the heart and of the central nervous system, inflammatory disorders and cancer. Various studies have shown the lack of harmonization of the results obtained with different methods, mainly due to different performances and measurements of S100B. The purpose of this work was to compare quantitatively the fully automated Elecsys® immunoassay with the reference immunoenzimatic method CanAg® EIA for serum S100B protein. In the study serum samples were analyzed of 161 patients: 85 females (aged 22-83 years) and 76 males (aged 16-90 years), affected by oncological and non-oncological pathologies. PassingBablok regression was used to analyze the comparison between the assays; it showed a strong interassay correlation: r = 0.9350 (95% CI =0.9122 0.9520), with an intercept of 0.02063 (95% CI=-0.02850 0.01400) and a slope of 1.1125 (95% CI=1.0200 1.2417). Elecsys® S100 assay should be preferred to CanAg® S100 for better standardization, good reliability and precision but also with the aim to reduce costs and obtain results in a shorter time.


Keywords

tumor marker;cancer;electro chemiluminescence immunoassay (ECLIA)


References

Supporting Agencies



Copyright (c) 2018 E Anastasi, G Gennarini, C Del Monte, B Colaprisca, S Tartaglione, C Di Segni, A Angeloni




This site is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).